Both respective authors contributed equally.
Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database
Article first published online: 26 DEC 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 28, Issue 1, pages 67–79, January 2014
How to Cite
for the German Sirolimus Study Group. Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database, , , , , , , , , , ,
Conflict of interest: None.
- Issue published online: 11 JAN 2014
- Article first published online: 26 DEC 2013
- Manuscript Accepted: 21 OCT 2013
- Pfizer Pharma GmbH
- mammalian target of rapamycin inhibitor;
- renal transplantation;
The German Sirolimus Study Group has established a database among 10 transplant centers throughout Germany to study the outcomes in 726 renal transplant patients being converted to a sirolimus-containing therapy between 2000 and 2008 with a total of more than 1500 recorded patient years on therapy. In this study, we present a detailed description of the cohort, of characteristic changes over the observation period, proteinuria and graft survival, and new-onset proteinuria after conversion. Over the study period, age, graft function at the time of conversion, and the proportion of patients switched to sirolimus because of malignancy increased, whereas the proportion of patients with significant proteinuria at conversion decreased. Already modest proteinuria (151–268 mg/L) at conversion and new-onset proteinuria (>500 mg/L) after conversion were associated with inferior graft survival. Even mild proteinuria (>71 mg/L) at conversion was associated with new-onset proteinuria (>500 mg/L) post-conversion. Serum creatinine and urinary protein excretion at conversion together with age at transplantation had a significant impact on patient and graft survival. This large data set confirms and extends previous observations that proteinuria is an important indicator for graft outcome after conversion to sirolimus. We conclude that patients without any proteinuria have the greatest benefit from conversion to sirolimus.